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Abstract
Background:  Recent genome-wide association (GWA) studies have identified several
unsuspected genes associated with type 2 diabetes (T2D) with previously unknown functions. In
this investigation, we have examined the role of 9 most significant SNPs reported in GWA studies:
[peroxisome proliferator-activated receptor gamma 2 (PPARG2; rs 1801282); insulin-like growth
factor two binding protein 2 (IGF2BP2; rs 4402960); cyclin-dependent kinase 5, a regulatory
subunit-associated protein1-like 1 (CDK5; rs7754840); a zinc transporter and member of solute
carrier family 30 (SLC30A8; rs13266634); a variant found near cyclin-dependent kinase inhibitor 2A
(CDKN2A; rs10811661); hematopoietically expressed homeobox (HHEX; rs 1111875);
transcription factor-7-like 2 (TCF7L2; rs 10885409); potassium inwardly rectifying channel subfamily
J member 11(KCNJ11; rs 5219); and fat mass obesity-associated gene (FTO; rs 9939609)].
Methods: We genotyped these SNPs in a case-control sample of 918 individuals consisting of 532
T2D cases and 386 normal glucose tolerant (NGT) subjects of an Asian Sikh community from
North India. We tested the association between T2D and each SNP using unconditional logistic
regression before and after adjusting for age, gender, and other covariates. We also examined the
impact of these variants on body mass index (BMI), waist to hip ratio (WHR), fasting insulin, and
glucose and lipid levels using multiple linear regression analysis.
Results: Four of the nine SNPs revealed a significant association with T2D; PPARG2 (Pro12Ala)
[odds ratio (OR) 0.12; 95% confidence interval (CI) (0.03–0.52); p = 0.005], IGF2BP2 [OR 1.37; 95%
CI (1.04–1.82); p = 0.027], TCF7L2 [OR 1.64; 95% CI (1.20–2.24); p = 0.001] and FTO [OR 1.46;
95% CI (1.11–1.93); p = 0.007] after adjusting for age, sex and BMI. Multiple linear regression
analysis revealed significant association of two of nine investigated loci with diabetes-related
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quantitative traits. The 'C' (risk) allele of CDK5 (rs 7754840) was significantly associated with
decreased HDL-cholesterol levels in both NGT (p = 0.005) and combined (NGT and T2D) (0.005)
groups. The less common 'C' (risk) allele of TCF7L2 (rs 10885409) was associated with increased
LDL-cholesterol (p = 0.010) in NGT and total and LDL-cholesterol levels (p = 0.008; p = 0.003,
respectively) in combined cohort.
Conclusion: To our knowledge, this is first study reporting the role of some recently emerged
loci with T2D in a high risk population of Asian Indian origin. Further investigations are warranted
to understand the pathway-based functional implications of these important loci in T2D
pathophysiology in different ethnicities.
Background
Type 2 diabetes (T2D) is a common disease characterized
by insulin resistance and reduced insulin secretion. It has
become a health problem world-wide and the underlying
molecular mechanisms involved in the development of
diabetes remain poorly understood. Linkage and candi-
date gene studies have been highly successful in identify-
ing genes for monogenic and syndromic forms of diabetes
[1]. However, this approach has yielded limited results in
mapping the genes for T2D [2-4]. The latest success of the
genome-wide association (GWA) studies using high den-
sity SNPs across the genome and complex genetic analyses
have identified several genes with previously unknown
functions [5-9].
In this investigation, we have examined the role of nine
most significant loci previously reported to be associated
with T2D in Caucasian populations [5,6,10-12] in a dia-
betic case-control cohort of Khatri Sikhs obtained from
North India. Our study is focused on the peroxisome pro-
liferator-activated receptor gamma 2 (PPARG2; Pro12 Ala;
rs1801282), insulin-like growth factor two binding pro-
tein 2 (IGF2BP2; rs 4402960), cyclin-dependent kinase 5,
a regulatory subunit-associated protein 1-like 1 (CDK5; rs
7754840), a zinc transporter and member of solute carrier
family 30 (SLC30A8; rs 13266634), a variant found near
cyclin-dependent kinase inhibitor 2A (CDKN2A; rs
10811661), hematopoietically expressed homeobox
(HHEX; rs 1111875), transcription factor-7-like 2
(TCF7L2; rs 10885409), potassium inwardly rectifying
channel subfamily J member 11 (KCNJ11; rs 5219), and a
recently discovered fat mass obesity-associated gene (FTO;
rs 9939609). TCF7L2 gene is the most frequently repli-
cated adult-onset T2D susceptibility gene [8]. Some of the
TCF7L2 variants have been found to strongly associated
with T2D in Asian Indian populations from South [13,14]
and South West India [14], and also our North Indian
cohort [15]. In this study, we have used the most signifi-
cant TCF7L2 SNP associated with T2D in Sikhs for com-
parisons. Since the replication of positive association in
multiple independently ascertained datasets from differ-
ent ethnic groups is crucial for identifying the true popu-
lation-specific susceptibility variants, we have examined
the role of polymorphisms of these nine genes in our dia-
betes case-control cohort of Asian Indian Sikhs.
Methods
Human Subjects
The study subjects are part of the ongoing Sikh Diabetes
Study (SDS) [16]. The focus of this study is on an endog-
amous community of Khatri Sikhs living in the Northern
states of India, including Punjab, Haryana, Himachal
Pradesh, Delhi, and Jammu & Kashmir. The DNA and
serum samples of 532 T2D cases (299 male, 233 female)
and 386 normal glucose tolerant (NGT) (184 male, 202
female) subjects were used in this investigation. Of the
532 cases, 324 are from family material (one index case
from each family) and the remaining 208 are unrelated
T2D cases from the same Sikh community. The cases were
25 or older with mean age at the time of recruitment
(mean ± SD) of 54.2 ± 11.0 yrs. The diagnosis of T2D was
confirmed by scrutinizing medical records for symptoms,
use of medication, and measuring fasting glucose levels
following the guidelines of American Diabetes Associa-
tion [17]. A medical record indicating either (1) a fasting
plasma glucose level ≥126 mg/dl or ≥7.0 mmol/l after a
minimum12-h fast or (2) a 2-h post glucose level [2-h oral
glucose tolerance test (OGTT)] ≥200 mg/dl or ≥11.1
mmol/l on more than one occasion with symptoms of
diabetes. IGT was defined as a fasting plasma glucose level
≥100 mg/dl (5.6 mmol/l) but ≤126 mg/dl (7.0 mmol/l)
or a 2-h OGTT ≥140 mg/dl (7.8 mmol/l) but ≤200 mg/dl
(11.1 mmol/l). In the absence of medical record informa-
tion, we confirmed self-reported T2D cases by performing
a 2-h OGTT. The 2-h OGTTs were performed following
the criteria of the World Health Organization (WHO) (75
g oral load of glucose). Body mass index (BMI) was calcu-
lated as [weight (kg)/height (meter)2], and waist-hip ratio
(WHR) was calculated as the ratio of abdomen or waist
circumference to hip circumference.
The NGT subjects participated in this study were from the
same Khatri Sikh community from which the T2D
patients were recruited [16]. Majority of the subjects were
recruited from the state of Punjab from Northern India.
Individuals of South, East and Central Indian origin, orBMC Medical Genetics 2008, 9:59 http://www.biomedcentral.com/1471-2350/9/59
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with type -1 diabetes or family member with type -1 dia-
betes, rare forms of T2D called maturity-onset diabetes of
young (MODYs), and secondary diabetes (e.g., hemo-
chromatosis, pancreatitis) were excluded from the study.
Of the 386 controls, 180 were normal spouses of diabetic
patients, and the remaining 206 were unrelated controls
who had no first degree relative affected with T2D, but
had other chronic illnesses such as hypertension, coro-
nary heart disease or arthritis. The selection of controls
was based on a fasting glycemia < 110 mg/dl or < 6.0
mmol/l or a 2-h glucose <140 mg/dl (< 7.8 mmol/l). Con-
trol subjects with HbA1c levels >6.5% were excluded. The
average age of NGT controls (mean ± SD) was 50.5 ± 13.8
yrs. Additionally, 22 subjects with IGT were excluded
from analyses. In general, Sikhs do not smoke for religious
and cultural reasons and about 50% of them were life
long vegetarians. Clinical characteristics of the SDS sub-
jects used for this investigation are summarized in Table
1. All blood samples were obtained at the baseline visit
and all participants provided a written informed consent
for investigations. All SDS protocols and consent docu-
ments were reviewed and approved by the University of
Oklahoma and the University of Pittsburgh Institutional
Review Boards as well as the Human Subject Protection
Committees at the participating hospitals and institutes in
India. Memorandum of understanding and material
transfer agreements for sample sharing and intellectual
property rights were signed between collaborating Indian
and the US Institutes. The study was approved by the
Indian Council of Medical Research, New Delhi and
Health Ministry Screening Committee, Union Ministry of
Health and Family Welfare, Government of India.
Metabolic Assays
Quantitation of lipids [total cholesterol, low-density lipo-
protein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, very low-density lipoprotein (VLDL)
cholesterol, triglycerides (TG)], insulin, and creatinine
levels were estimated in serum. HbA1c was quantified in
whole blood. Lipids were quantified by using standard
enzymatic methods (Roche, Basel, Switzerland). HbA1c
levels were determined by turbidometric inhibition
immunoassay (Tina Quant; Roche, Basel, Switzerland).
Creatinine was quantified by using kinetic colorimetric
assay (Roche, Basel, Switzerland). Insulin was measured
by radio-immuno assay (Diagnostic Products, Cypress,
USA). All quantitative parameters were determined by fol-
lowing manufacturer's instructions using Hitachi 902
auto-analyzer (Roche, Basel, Switzerland).
SNP Genotyping
DNA was extracted from buffy coats using QiaAmp blood
kits (Qiagen, Chatworth, CA) or by the salting out proce-
dure [18]. Genotyping for all investigated SNPs was per-
formed using TaqMan Pre-Designed or TaqMan Made-to
Order SNP genotyping assays from Applied Biosystems
(ABI, Foster City, USA). TaqMan genotyping reactions
were performed on ABI 7900 genetic analyzer using 2 ul
Table 1: Clinical characteristics of study population stratified by gender (Mean ± SD)
T2D Cases NGT
Gender 532 (299M/233F)* 386 (184M/202F) pvalue**
Age (yrs) M* 53. 2 ± 11.1 51.7 ± 15.6 0.006
F 55.2 ± 11.0 50.8 ± 13.0 0.001
Age at
diagnosis (yrs) M 47.5 ± 10.9 -- --
F 48.2 ± 10.5 -- --
Duration of
Diabetes (yrs) M 8.6 ± 7.4 -- --
F 7.3 ± 6.0 -- --
BMI M 26.6 ± 4.3 26.6 ± 4.4 0.912
F 29.0 ± 5.5 27.5 ± 4.9 <0.001
WHR† M 0.99 ± 0.06 0.97 ± 0.07 0.002
F 0.93 ± 0.07 0.91 ± 0.07 <0.001
Fasting Glucose
(mmol/l) M 10.1 ± 3.7 5.4 ± 0.6 <0.0001
F 10.0 ± 3.5 5.4 ± 0.5 <0.0001
Fasting
Insulin(IU/ml) M 9.1 ± 7.9 11.0 ± 9.2 0.057
F 8.8 ± 7.4 11.5 ± 9.5 0.002
HbA1c (%) M 8.6 ± 2.4 5.6 ± 0.7 <0.0001
F 8.6 ± 2.5 5.6 ± 0.7 <0.0001
*M – male, F – female; †Waist to hip ratio; ** Difference between T2D cases and NGT controlsBMC Medical Genetics 2008, 9:59 http://www.biomedcentral.com/1471-2350/9/59
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of (10 ng/ul) of genomic DNA following manufacturer's
instructions. Florescence was detected on an ABI prism
7900HT sequence detection system (ABI, Foster City,
USA). Genotypes were scored by analyzing data on both
real-time as well as allele discrimination assay platforms
using SDS software provided by the ABI. Data quality for
SNP genotyping was checked by establishing reproduci-
bility of control DNA samples. For quality control, 30 rep-
licate positive controls and 8 negative controls were
included in each run to match the concordance, and the
discrepancy in the concordance was < 0.2%. Genotyping
success rate ranged from 96%–99.8% for all the investi-
gated SNPs except for CDKN2A (rs 10811661) for which
the success rate was 88.5% due to technical difficulties.
Statistical Analysis
We evaluated Hardy-Weinberg equilibrium using a one-
degree of freedom goodness-of-fit test separately among
cases and controls using Pearson chi-square test. The allele
frequencies in T2D cases were compared to those in con-
trols using chi-square test or Fisher's exact probability test,
where appropriate. Statistical evaluations for testing
genetic effects of association between the case-control sta-
tus and each individual SNP, measured by the odds ratio
(OR) and its corresponding 95% confidence limits were
estimated using unconditional logistic regression before
and after adjusting for age, gender, and other covariates.
Association analyses were performed assuming a domi-
nant, recessive and co-dominant effect for each polymor-
phism using SNPassoc [19]. In all analyses, the common
homozygote genotype in the control population was
defined as the reference category. The likelihood ratio test
was used to test the effect of each SNP at the nominal 5%
significance level. Akaïke's information criterion [20] was
also used to select the best genetic model for each SNP.
We also performed multiple linear regression analysis to
examine the impact of these variants on quantitative risk
variables of T2D, including fasting insulin, glucose, and
lipid levels. Skewed variables for the continuous traits
(e.g., triglycerides, cholesterol, LDL, glucose) were log-
transformed before statistical comparisons. Significant
covariates for each dependent trait were identified by
using Spearman's correlation and step-wise multiple lin-
ear regression with an overall 5% level of significance.
Results
We genotyped nine SNPs, including the six SNPs from
newly emerged gene regions recently identified by multi-
ple GWA studies [5-7,9,21], in a case-control cohort of
Asian Indian Sikhs consisting 918 subjects including, 532
T2D cases and 386 NGT controls matched for ethnicity
and geographic origin. Table 1 shows the clinical and
physical characteristics of the study subjects separated by
gender. The information on chromosomal position and
genomic locations of the investigated SNP, base change,
genotype, allele frequencies, and ORs is summarized in
Tables 2. Genotype distribution for all investigated SNPs
was in Hardy-Weinberg equilibrium in both cases and
controls. The genes containing SNPs that showed strong
association with T2D in our sample were PPARG2
(rs18081282),  IGF2BP2  (rs 4402960), TCF7L2
(rs10885409), and FTO (rs9939609). The frequencies of
major alleles (at risk allele) of PPARG2 and minor alleles
(at risk allele) of IGF2BP2, TCF7L2 and FTO were signifi-
cantly higher among diabetics than controls (Tables 2).
The adjusted ORs under a recessive model provided a
strongest evidence of association for PPARG2 [OR 0.12;
95% CI (0.03–0.52); p = 0.005] showing protective asso-
ciation with T2D for the less common Ala (G) allele. On
the other hand, dominant models suggested strongest
association for the other three genes: OR for IGF2BP2
[1.37; 95% CI (1.04–1.82); p = 0.027], OR for TCF7L2
[1.64; 95% CI (1.20–2.24); p = 0.001] and OR for FTO
[1.46; 95% CI (1.11–1.93); p = 0.007] when T2D subjects
were compared with NGT. However, our study could not
replicate the significant association of the remaining five
SNPs reported in earlier studies by analyzing each SNP
individually.
To explore the possible mechanisms of action of these var-
iants for affecting T2D susceptibility, we tested the associ-
ation of these SNPs with the T2D-related quantitative
phenotypes (height, weight, BMI, WHR, insulin, creati-
nine, total cholesterol, LDL-cholesterol, VLDL-choles-
terol, HDL-cholesterol, and triglycerides) using multiple
linear regression analysis in NGT after adjusting for the
effects of age, sex, BMI, disease status, and medication. As
shown in Table 3, the 'C' (risk) allele of CDK5 variant was
significantly associated with decreased HDL-cholesterol
levels in NGT (p = 0.005) as well as combined
(NGT+T2D) sample (p = 0.005). The less common 'C'
(risk) allele of TCF7L2 polymorphism also showed signif-
icant association with increased levels of LDL-cholesterol
in NGT (p = 0. 010) and total and LDL-cholesterol in
combined sample (p = 0.008; p = 0.003, respectively).
Discussion
In this investigation, we have carried out an unbiased rep-
lication of SNPs associated with T2D susceptibility in
recently published multiple GWA studies [5-8] in our
independent dataset of Asian Indian origin. Two of these
SNPs belong to highly replicated biological candidate
genes  PPARG2  (Pro12Ala; rs 1801282) and KCNJ11
(Glu23Lys; rs 5219) that produced unequivocal evidence
of their involvement in T2D in several independent stud-
ies performed in different data sets [22,23]. Moreover,
these two genes are also targets for anti-diabetic therapies.
PPARG2 encodes a transcription factor involved in adi-
pocyte differentiation and is the target of thizolodinedi-
one class of drugs used for T2D [24] and KCNJ11 is theBMC Medical Genetics 2008, 9:59 http://www.biomedcentral.com/1471-2350/9/59
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Table 2: Candidate gene polymorphisms and type 2 diabetes risk in Khatri Sikhs; comparing NGT vs. T2D
ODDS RATIO (ORs*) 
GENE/SNP CHROMO 
SOME
POSITIONψ GENOTYPE NGT (%) T2D (%) CO-
DOMINANT 
DOMINANT RECESSIVE 
OR (95% CI) OR (95% CI) OR (95% CI)
PPARG2 3 12336825
rs 1801282 CC 286 (76.5) 414 (80.4) CC vs. CG, GG CC vs. CG+GG CC+CG vs. GG
CG 78 (20.8) 99 (19.2) 0.96 (0.68–1.35) 0.84 (0.61–1.17) 0.12 (0.03–0.52)
GG 10 (2.7) 2 (0.4) 0.11 (0.03–0.51)
Allele C 0.87 0.90 CG; p = 0.824 p = 0.300 p = 0.005
Allele G 0.13 0.10 GG; p = 0.005
IGF2BP2 3 186994381
rs 4402960 GG 150 (38.9) 160 (31.1) GG vs. GT, TT GG vs. GT+TT GG+GT vs. TT
GT 173 (44.8) 262 (51.0) 1.36 (1.01–1.84) 1.37 (1.04–1.82) 1.18 (0.82–1.68)
TT 63 (16.3) 92 (17.9) 1.42 (0.95–2.10)
Allele G 0.61 0.57 GT; p = 0.041 p = 0.027 p = 0.372
Allele T 0.39 0.43 TT; p = 0.087
CDK5 6 20769229
rs 7754840 GG 203 (55.2) 281 (53.7) GG vs. CG, CC GG vs. CG+CC GG+CG vs. CC
CG 134 (36.4) 196 (37.5) 1.04 (0.78–1.40) 1.06 (0.80–1.37) 1.10 (0.68–1.78)
CC 31(8.4) 46 (8.8) 1.12 (0.68–1.83)
Allele G 0.73 0.55 CG; p = 0.771 p = 0.688 p = 0.692
Allele C 0.27 0.45 CC; p = 0.655
SLC30A8 8 118253964
rs 13266634 CC 188 (53.9) 290 (54.5) CC vs. CT, TT CC vs. CT+TT CC+CT vs. TT
CT 135 (38.7) 195 (36.6) 0.95 (0.71–1.27) 0.99 (0.75–1.30) 1.23 (0.74–2.02)
TT 26 (7.4) 47 (8.8) 1.21 (0.72–2.04)
Allele C 0.73 0.73 CT; p = 0.718 p = 0.946 p = 0.424
Allele T 0.27 0.27 TT; p = 0.468
CDKN2A 9 22124094
rs 10811661 TT 232 (78.6) 427 (82.7) TT vs. CT, CC TT vs. CT+CC TT+CT vs. CC
CT 61 (20.6) 87 (16.9) 0.85 (0.58–1.23) 0.84 (0.58–1.21) 0.54 (0.08–3.93)
CC 2 (0.7) 2 (0.4) 0.51 (0.07–3.73)
Allele T 0.89 0.91 CT; p = 0.386 p = 0.343 p = 0.545
Allele C 0.11 0.09 CC p = 0.511
HHEX 10 94452862
rs 1111875 TT 120 (32.7) 154 (30.0) TT vs. CT, CC TT vs. CT+CC TT+CT vs. CC
CT 166 (45.2) 242 (47.0) 1.28 (1.02–1.90) 1.22 (0.93–1.60) 1.10 (0.82–1.47)
CC 81 (22.1) 118 (23.0) 1.16 (0.80–1.67)
Allele T 0.55 0.54 CT; p = 0.107 p = 0.147 p = 0.529
Allele C 0.45 0.46 CC; p = 0.438
TCF7L2 10 114798062
rs 10885409 TT 118 (31.7) 112 (21.8) TT vs. TC, CC TT vs. TC+CC TT+TC vs. CC
CT 169 (45.4) 257 (50.0) 1.59 (1.14–2.23) 1.64 (1.20–2.24) 0.76 (0.55–1.03)
CC 85 (22.8) 145 (28.2) 1.72 (1.18–2.53)
Allele T 0.54 0.47 TC; p = 0.006 p = 0.001 p = 0.078
Allele C 0.46 0.53 CC; p = 0.003
KCNJ11 11 17366148
rs 5219 CC 148 (39.6) 226 (42.5) CC vs. CT. TT CC vs. CT+TT CC+CT vs. TT
CT 169 (45.2) 247 (46.4) 0.97 (0.73–1.30) 0.90 (0.69–1.19) 0.71 (0.48–1.06)
TT 57 (15.2) 59 (11.1) 0.70 (0.46–1.08)
Allele C 0.66 0.62 CT; p = 0.835 p = 0.458 p = 0.091
Allele T 0.34 0.38 TT; p = 0.110
FTO 16 52378028
rs 9939609 TT 175 (49.6) 205 (39.9) TT vs. AT, AA TT vs. AT+AA TT+AT vs. AA
AT 137 (38.8) 244 (47.6) 1.51 (1.30–3.03) 1.46 (1.11–1.93) 1.08 (0.71 – 
1.64)
AA 41 (11.6) 64 (12.5) 1.32 (0.84–1.93)
Allele T 0.69 0.64 AT; p = 0.006 p = 0.007 p = 0.737
Allele A 0.31 0.36 AA; p = 0.227
*ORs were adjusted for age, sex, and BMI; ψ Position of SNPs on chromosome has been taken from NCBI (Genome Build 36.3)BMC Medical Genetics 2008, 9:59 http://www.biomedcentral.com/1471-2350/9/59
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target of sulphonylurea class of drugs extensively used for
treating neonatal diabetes [25,26]. The remaining seven
variants (IGF2BP2,  CDK5,  SLC30A8,  CDKN2A,  HHEX,
TCF7L2 and FTO) evaluated in this study are from the
recently identified gene regions that provide convincing
evidence of their involvement in T2D in fine mapping and
multiple GWA studies.
We have identified a significant association of PPARG2
(rs1801282; p = 0.005), IGF2BP2 (rs 4402960; p = 0.027)
and FTO (rs 9939609; p = 0.007) variants with T2D along
with the TCF7L2 variant (rs10885409; p = 0.001) in our
Asian Indian population. The protective association of the
less common 'Ala' allele at codon 12 of PPARG2 gene has
been consistently reproduced in multiple independent
studies conducted in different populations [22,27-31]
with few exceptions of small studies e.g. Oji-Cree [32] and
Czech [33], where the Ala allele was shown to be associ-
ated with T2D risk. The protective association of Ala allele
was also not confirmed in a South Indian population
[34]. The observed difference of association within Asian
Indian populations is important in view of the extensive
diversity present between Indian populations [35-37].
IGF2BP2 belongs to a family of three mRNA binding pro-
teins; the human growth hormone gene and insulin like
growth factor 1 and 2 genes. It is involved in pancreas
development, growth and stimulation of insulin action
[38,39]. We have replicated a significant association of
IGF2BP2 (rs 4402960) SNP reported earlier in three differ-
ent GWA studies [5,11,12], meta analysis of three GWA
studies [7], and also in Japanese population [40]. How-
ever, no association of this variant was noticed with any
quantitative trait related to glucose homeostasis or lipid
metabolism.
The FTO gene is of unknown function that was originally
cloned as a result of identification of fused toe mutant
mouse [41]. Recently, the recombinant murine fto has
been shown to be involved in nucleic acid methylation by
catalyzing Fe (II) – and 2-oxoglutarate (2OG)-dependent
dioxygenases [42,43]. This locus is associated with child-
hood and adult obesity in several European and US pop-
ulations [9,44,45]. The FTO variant (TA A) (rs 9939609)
has also been shown to be strongly associated with T2D
risk (OR 1.27; p = 5 × 10-8) in GWA scan performed in UK
population [9]. Our study also confirmed significant asso-
ciation of FTO  (rs 9939609) variant with T2D in this
Asian Indian sample. But the mechanism by which it
relates to obesity and T2D in humans is still unclear. Stud-
ies have shown that T2D risk associated with 'A' allele of
this variant (rs 9939609) is strongly mediated by BMI,
and has been shown to potentially affect mass rather than
height [9]. In contrast, in this Asian Indian sample, the
T2D risk does not seem to be mediated by BMI or weight,
as by excluding BMI, the risk associated with this variant
did not disappear, as reported in other studies [9,40]. Per-
haps the ethnic difference could be responsible for this
difference. Moreover, BMI is not considered an accurate
measure for obesity, especially in the populations from
South Asia where at a given BMI, their muscle mass is low
and visceral and subcutaneous fat is increased [46-48].
Therefore, measures of BMI or waist and hip may not
reveal accurate estimates of total fat.
The importance of TCF7L2 as diabetes gene is now very
well established across ethnicities but many more genes
for diabetes especially in non-white ethnicities still
remain to be identified. It is interesting to observe that the
risk alleles found to be associated with T2D in this Asian
Indian population in four significant SNPs (PPARG2,
IGF2BP2, TCF7L2 and FTO) were consistent with those
reported in GWA studies in Caucasians and Japanese
[5,7,11,40]. However, it is still unclear how these loci con-
tribute to T2D risk as none of these variant was found to
influence insulin or fasting glucose levels in this study.
More functional studies would be needed to clearly define
Table 3: SNPs with significant association to quantitative phenotypes of T2D
Gene/SNP Risk Allele Trait associated with T2D R-Square p (adjusted)
NGT Subjects¥
CDK5 C HDL-cholesterol ↓ Φ 0.021 0.005
rs 7754840
TCF7L2 C Total-cholesterol ↑ 0.004 0.083
rs 10885409 LDL-cholesterol↑ 0.016 0.010
Combined**
NGT, T2D
CDK5 C HDL-cholesterol ↓ 0.021 0.005
rs 7754840
TCF7L2 C Total-cholesterol↑ 0.009 0.008
rs 10885409 LDL-cholesterol↑ 0.012 0.003
¥ Multiple linear regression analyses were adjusted for age, sex, BMI, and medication; **Multiple linear regression analyses were adjusted for age, 
sex, BMI, disease status, and medication; Φ Arrows indicate risk-allele associated increase or decrease in quantitative trait.BMC Medical Genetics 2008, 9:59 http://www.biomedcentral.com/1471-2350/9/59
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the role of these variants in glucose homeostasis. Perhaps
the causal variants in these genes controlling insulin secre-
tion and insulin resistance are yet to be identified. With
regard to remaining loci, our study did not confirm the
previous reported association of variants (KCNJ11, CDK5,
SLC30A8, CDKN2A and HHEX) when each SNP was ana-
lyzed separately. With the exception of CDK5  and
TCF7L2, no other gene variant showed significant associ-
ation with any diabetes-related quantitative traits. The 'C'
(risk) allele of CDK5 variant was associated with signifi-
cantly reduced HDL levels (p = 0.005) in this sample. The
possibility of false positive results in our sample cannot be
ruled out because of relatively small size of our cohort.
Also, while our manuscript was being reviewed, publica-
tion of two large meta-analysis studies on lipid traits in
subjects with coronary artery disease and T2D did not
report this locus affecting lipid traits in Caucasians
[49,50]. However, as we previously reported [15], five
SNPs in the TCF7L2  gene (rs 7901695, rs7903146,
rs11196205, rs10885409, and rs 12255372) revealed sig-
nificantly elevated gene-dosage effects on total choles-
terol, LDL cholesterol and VLDL cholesterol levels in this
Khatri Sikh sample. It is therefore possible that the
observed association with quantitative lipid levels could
be population-specific and may not be present in other
ethnicities. Replication of these findings in a larger sample
of Asian Indian origin would be required confirm these
findings.
On the other hand, the absence of positive association
with T2D in remaining loci may suggest that the genetic
variation in some loci could be restricted to a particular
genetic background and environment and the contribu-
tion of these loci in Indian population may be minor.
Alternatively, different SNPs within the same gene could
be contributing to the risk and could be population spe-
cific. Therefore, further SNP screening and deep sequenc-
ing of these genes would be required to identify putative
ethnicity-specific functional variants in these novel candi-
dates.
Conclusion
Our study in Asian Indian Sikhs has successfully repli-
cated the association of four of nine loci recently reported
to be associated with T2D in Caucasians. To our knowl-
edge, this is the first report describing the role of some
recently emerged loci with T2D in a population of Asian
Indian origin from North. Further investigations are war-
ranted to cross-validate these findings in other larger data-
sets. Functional studies would help understand the
pathway-based implications of these important loci in
T2D pathophysiology in different ethnicities.
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